Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle Toxin Conjugate BT8009 in Patients with Advanced Solid Tumors

Business WireSeptember 24, 2020

Tag: Bicycle Therapeutics , BT8009 , Nectin-4 , RP2D

PharmaSources Customer Service